News

Fri, 2021-07-30 14:59
Anant Madabhushi, PhD, is named to the 2021 Pathologist's Power List
Friday, July 30, 2021 - 14:59

Dr.Anant Madabhushi is named a Showstopper on The Pathologist’s 2021 Power List. This list celebrates 100 influential figures, thought leaders, and opinion shapers in pathology and laboratory medicine. Dr. Madabhushi was also named to the Power List in 2019 and 2020. 

For more information read more about this placement on The Pathologist’s website.

Thu, 2021-07-29 15:01
CCIPD Article in Top 10% Most Cited on PLOS ONE
Thursday, July 29, 2021 - 15:01

A CCIPD article is among the Top 10% Most Cited PLOS ONE papers published in 2018. Congratulations to CCIPD authors Andrew Janowczyk, PhD and Anant Madabhushi, PhD on this recognition of their paper titled, “A deep-learning classifier identifies patients with clinical heart failure using whole-slide images of H&E tissue.” As of the time of recording, the article has been cited 49 times and counting!

Further congratulations to authors Jeffery Nirschl (first author), Eliot G. Peyster, Renee Frank, Kenneth Margulies and Michael Feldman.

To learn more, read the article on PLOS ONE.

Mon, 2021-07-26 15:01
A CCIPD at CWRU, Cleveland Clinic collaboration receives $2.95 million grant from the National Institutes of Health
Monday, July 26, 2021 - 15:01

The four-year, $2.95 million NIH grant will be used to fund a research consortium exploring how imaging can be used to predict the risk of atrial fibrillation recurrence. The study will use Artificial Intelligence to develop and validate a new risk prediction tool. 

Read more about this grant from CWRU’s The Daily.

Sun, 2021-07-11 13:59
Dr. Madabhushi pens Crain’s Cleveland piece on AI and health disparities
Sunday, July 11, 2021 - 13:59

Dr. Madabhushi’s piece, “Personal View: Tackling racial health disparities with artificial Intelligence”, discusses the use of AI to tackle racial health disparities and highlights a recent partnership between CCIPD at CWRU and Hampton University to use AI to improve prostate cancer care. Read the full article on Crain's Cleveland Business